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serum amyloid A binds to 
fibrin(ogen), promoting fibrin 
amyloid formation
Martin J. Page1, Greig J. A. thomson1, J. Massimo Nunes1, Anna-Mart Engelbrecht1,  
theo A Nell  1, Willem J. S. de Villiers1,2, Maria C. de Beer3, Lize Engelbrecht4, 
Douglas B. Kell1,5,6,7 & etheresia pretorius  1
Complex associations exist between inflammation and thrombosis, with the inflammatory state 
tending to promote coagulation. Fibrinogen, an acute phase protein, has been shown to interact 
with the amyloidogenic ß-amyloid protein of Alzheimer’s disease. However, little is known about 
the association between fibrinogen and serum amyloid A (SAA), a highly fibrillogenic protein that is 
one of the most dramatically changing acute phase reactants in the circulation. To study the role of 
SAA in coagulation and thrombosis, in vitro experiments were performed where purified human SAA, 
in concentrations resembling a modest acute phase response, was added to platelet-poor plasma 
(PPP) and whole blood (WB), as well as purified and fluorescently labelled fibrinogen. Results from 
thromboelastography (TEG) suggest that SAA causes atypical coagulation with a fibrin(ogen)-mediated 
increase in coagulation, but a decreased platelet/fibrin(ogen) interaction. In WB scanning electron 
microscopy analysis, SAA mediated red blood cell (RBC) agglutination, platelet activation and 
clumping, but not platelet spreading. Following clot formation in PPP, the presence of SAA increased 
amyloid formation of fibrin(ogen) as determined both with auto-fluorescence and with fluorogenic 
amyloid markers, under confocal microcopy. SAA also binds to fibrinogen, as determined with a 
fluorescent-labelled SAA antibody and correlative light electron microscopy (CLEM). The data presented 
here indicate that SAA can affect coagulation by inducing amyloid formation in fibrin(ogen), as well 
as by propelling platelets to a more prothrombotic state. The discovery of these multiple and complex 
effects of SAA on coagulation invite further mechanistic analyses.
Serum amyloid A (SAA) refers to a highly conserved family of apoproteins that are synthesised predominantly by 
the liver1 and are transported in the circulation, mainly associated with high-density lipoprotein (HDL)2. Their 
description nearly 40 years ago was the result of analyses of amyloid A (AA) fibrils that allowed for the identi-
fication of the precursor SAA apolipoprotein3. During inflammatory processes, cytokines induce hepatic SAA 
synthesis. The secreted SAA associates with circulating HDL and the plasma concentration can increase 1000-fold 
or more, to levels exceeding 1 mg.mL−1 4. SAA profoundly alters HDL composition and structure, with implica-
tions for the dynamics of the lipid and apolipoprotein components that constitute the HDL particle5. SAA, either 
produced locally (e.g. in the gut epithelium or by resident macrophages) or transported to sites of inflammation, 
also forms part of the innate immune system where it activates the inflammasome cascade, leading to immune 
activation and immunomodulation6. It is this proinflammatory function of SAA that could explain the strong 
relationship between SAA levels and future cardiovascular events7,8. Indeed, a question is whether increased levels 
of circulating SAA promote a prothrombotic state in conditions such as acute coronary syndromes9.
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Recently we reported that during inflammation, likely due to the presence of highly substoichiometric 
amounts of lipopolysacharide (LPS) and the broadly equivalent lipoteichoic acids (LTA)10, plasma fibrinogen 
molecules become amyloidogenic, and are associated with an enhanced prothrombotic state9–11. The amyloi-
dogenic potential of fibrinogen became apparent with the description that rare sequence variants of fibrino-
gen in the A alpha-chain (AFib) can deposit as amyloid fibrils, resulting in predominantly renal amyloidosis12. 
Amyloidogenesis is the result of misfolding of precursor proteins with uncoiling of alpha helices and increases in 
β-sheet structure13,14. These misfolded protein structures likely lead to functional effects including a tendency to 
promote thrombosis9.
Fibrinogen and SAA are both acute phase proteins15. SAA is also a highly fibrillogenic molecule16 and chroni-
cally elevated levels may cause reactive systemic amyloidosis (AA type). High plasma concentrations of SAA can 
result in aggregation as amyloid in β-sheet fibrillar deposits17. It is possible that both SAA and fibrinogen could 
co-deposit in such fibrils.
Although it is well-known that SAA is an excellent biomarker for inflammation, little is known about its 
potential to induce amyloid changes in fibrin(ogen), which could ultimately promote hypercoagulation and 
abnormal clotting. Platelets, erythrocytes (RBCs) and circulating plasma molecules all interact and play a funda-
mental role in normal haemostasis and blood clotting, and in the presence of inflammation can undergo inflam-
matory changes themselves18–21. Since fibrinogen can also interact with other amyloidogenic proteins such as 
Alzheimer’s disease peptide beta-amyloid22–24, the aim of this paper was therefore to examine the amyloidogenic 
propensity of free SAA when interacting with fibrin(ogen) in the blood of healthy individuals, and in a purified 
fibrinogen model. Further to this, SAA has also been shown to bind to platelets25 and impact platelet activation26. 
We also explored the effect of SAA on human fibrin clot properties, as well as platelet function and morphology.
Materials and Methods
Blood samples. Healthy female donors (N = 21), aged 29 to 59, were recruited for this ex vivo study (see 
Table 1 for demographic data). Exclusion criteria were known acute and chronic inflammatory conditions, smok-
ing, and contraceptive or hormone replacement treatment. To prevent gender differences as confounding factors, 
we included only female donors. We included individuas with a BMI between 20 and 33. This population did not 
take any anti-inflammatory medication and their baseline C-reactive protein (CRP) and SAA levels were meas-
ured (Table 1). Blood was collected in citrated tubes by a qualified phlebotomist and left to stand for 30 minutes. 
Whole blood and platelet poor plasma were used in this study. Whole blood was kept at room temperature and 
analysed on the day of collection. Platelet poor plasma was derived by centrifuging whole blood for 15 minutes at 
3000 g and stored at −80 °C. We also used pooled platelet poor plasma as one of our models. As positive control 
to show platelet activation and spreading, we include a figure from type 2 diabetes (T2DM); this is from raw data 
from a recently published paper27. This is how platelets look like in T2DM, which is a condition that is known to 
have platelets in a typical prothrombotic state - where both platelet hyperactivation and spreading occurs.
Purification of human acute phase HDL (AP HDL), SAA and apoA-I. Blood for the purification of 
acute phase HDL was obtained at the University of Kentucky Medical Center, from patients post cardiac surgery, 
with informed consent (IRB 04-0218-P2J).
Demographic data (N = 21; all female)
Attribute Value
Reference Values (from Pathology Laboratory: 
Pathcare, Stellenbosch, South Africa)
Age (yrs) 48.05 ± 1.78
Height (m) 1.69 [1.58–1.73]
Weight (kg) 76.8 ± 4.78
BMI (kg.m−2) 26.9 [20.55–33.65]
GLU (mmol.L−1) 4.85 ± 0.13 3.5–5.5 mmol.L−1
TC (mmol.L−1) 5.48 ± 0.24 <5.0 mmol.L−1
HDL-C (mmol.L−1) 1.6 [1.35–1.75] >1.0 mmol.L−1
LDL-C (mmol.L−1) 3.30 ± 0.19 <3.0 mmol.L−1
TG (mmol.L−1) 1.04 [0.85–1.74] <1.70 mmol.L−1
Non-HDL (mmol.L−1) 3.92 ± 0.21 <3.8 mmol.L−1
TC:HDL 3.55 ± 0.14 <4.0
Ultra-sensitive CRP (mg.L−1) 2.5 ± 0.4
<1 mg. L−1 – low risk1–3 mg. L−1 – moderate risk
>3 mg. L−1 – high risk
>5.0 mg. L−1 – active infection/inflammation
SAA levels (µg.mL−1) 1.5 [0.7–2.2]
Table 1. Control donor data. Parametric measures are reported as mean ± SEM. Non-parametric data 
are reported as median [interquartile range]. Parameters assessed by the pathology laboratory also 
indicate the provided reference values. BMI = Body Mass Index; GLU = blood glucose; TC = total 
cholesterol; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; 
TG = triglycerides; Non-HDL = non-high density lipoprotein cholesterol; TC:HDL = total cholesterol to high 
density lipoprotein cholesterol ratio; CRP = C-reactive protein.
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Human HDL containing SAA (known as acute phase HDL) was purified by sequential ultracentrifugation 
from plasma collected 24 hours after cardiac surgery as described28. SAA and apoA-I were purified from delipi-
dated acute phase HDL by size-exclusion chromatography as described29.
Product incubation with samples. The SAA levels of each of our healthy control donors were determined 
to confirm that they present in the normal range (Table 1). Purified SAA was added to donor platelet poor plasma 
(PPP) and whole blood (WB) ex vivo or to purified fibrinogen (Sigma, F3879) and FITC-labelled fluorescent 
fibrinogen (abcam, ab92811) in vitro at a final concentration of 30 or 100 μg.mL−1. This level is similar to that 
characterising a modest acute phase response30. A working solution of 0.166 and 2 mg.mL−1 purified fibrinogen 
was used and found to be a suitable concentration to form fibrin fibres in the presence of thrombin, similar to that 
of platelet-rich plasma fibres from healthy individuals11. ApoA-I (30 μg.mL−1) added to pooled PPP and purified 
fibrinogen was used as a negative control for the confocal experiment.
Thromboelastography (TEG) with WB and PPP. A Thromboelastograph 5000 Hemostasis Analyzer 
System was used for viscometric clot property studies of whole blood (WB) and platelet poor plasma (PPP). WB 
and PPP were exposed for 10 minutes to SAA (30 μg.mL−1) before being analysed by TEG. 340 μL of exposed or 
naïve sample were added to 20 μL of 0.2 M CaCl2 in a disposable TEG cup to reverse the anticoagulant effect of the 
citrate. TEG assesses various kinetic clot parameters: i.e. R-time (clot initiation time, measured in minutes), Angle 
(the thrombin burst, measured as the slope between R and the 20 mm set point), MA (the maximum amplitude 
and the overall stability of the clot), MRTG (the maximum velocity of clot growth), TMRTG (the time of maxi-
mum rate of thrombin generation) and TTG (the total clot strength)19,31–33. This method is based on activation 
via the intrinsic clotting pathway upon re-calcification of a citrated anticoagulant sample, and contact activation 
between the manufacture-supplied cup and pin surface.
Scanning Electron Microscopy (SEM) with WB and purified fibrinogen. SEM was used to study 
the ultrastructure of RBCs and platelets in whole blood, with a specific focus on their membranes. WB smears 
were prepared on the day of blood collection by pipetting 10 μL of the treatment groups (naïve or 30 μg.mL−1 
SAA-exposed) onto a glass cover slip. After leaving to settle for 1 minute, preparation involved washing with PBS, 
4% formaldehyde and 1% osmium tetroxide fixation steps, and dehydration in increasing grades of ethanol and 
99.9% hexamethyldisilazane (HMDS) [for detailed methods see19,34]. Images were captured using a Zeiss Merlin 
(Gemini II) FE SEM. A purified fibrinogen sample without thrombin (i.e. no clot initiation) was also prepared 
for SEM analysis to determine if SAA causes the soluble fibrinogen proteins to form insoluble matted deposits.
Confocal Microscopy with purified fibrinogen and FITC-fibrinogen. Purified fibrinogen. To study 
the protein structure and nature of purified fibrinogen upon exposure to SAA (30 μg.mL−1), we first imaged 
unstained samples, followed by the addition of amyloid-specific markers. The three fluorescent amyloid markers 
were prepared as follows: 5 µM thioflavin T (ThT), 0.1 µL (stock concentration as supplied) of Amytracker 480 
and 0.1 µL (stock concentration as supplied) of Amytracker 6809,10 were added to the sample to incubate for 
30 minutes. A working solution of Amytrackers was made in PBS at a 1:20 ratio. The exposure concentration of 
the working solution calculates back to 0.1 µL of stock solution as supplied.
Clots were made from the naïve or SAA-treated purified fibrin(ogen) by adding thrombin. Thrombin (South 
African National Blood Service) was solubilized in PBS containing 0.2% human serum albumin to obtain a con-
centration of 20 U.mL−1 and was used at a 1:2 ratio to create extensive fibrin networks. A coverslip was placed over 
the prepared clot, and samples were viewed using a Zeiss LSM 780 with ELYRA PS1 confocal microscope using 
a Plan-Apochromat 63x/1.4 Oil DIC objective. ThT was excited by the 488 nm laser35, with emission measured at 
508 to 570 nm; Amytracker 480 was excited by the 405 nm laser, with emission measured at 478 to 539 nm; and 
Amytracker 680, was excited by the 561 nm laser, with emission measured at 597 to 695 nm. A selection of micro-
graphs of the prepared clots was captured. Gain settings were kept the same for all data acquisition and used for 
statistical analyses; however, brightness and contrast were slightly adjusted for figure preparation.
FITC-fluorescent human fibrinogen. We added SAA (30 μg.mL−1) to FITC-fluorescent human fibrinogen, fol-
lowed by thrombin, to create an extensive fibrin fibre network. FITC was excited at 488 nm, with emission meas-
ured at 508 to 570 nm. Amytracker 680 was added to FITC fibrinogen to visualise amyloid areas (emission and 
excitation as above).
Confocal Microscopy with individual and pooled platelet poor plasma (PPP) clots. Individual 
donor PPP to detect amyloid. Individual platelet poor plasma (PPP) samples from healthy individuals were 
stored at −80 °C. On the day of analysis, the −80 °C stored PPPs were brought to room temperature. Naïve and 
SAA-exposed samples were prepared, with exposed samples incubated for 10 minutes with SAA. Here, all three 
fluorescent markers were added into the same sample. Thrombin was added (see above) to create extensive clots. 
The fluorescent signal of each of the three fluorescent markers was captured as a composite image file in the Zeiss 
ZEN software, whereupon ImageJ (FIJI) was used to split and analyse the RGB channels. The variance between 
(black) background and the presence of fluorescent pixels (binary comparison) were assessed for each of the 
three fluorescent markers in the clots. See10,36 for a detailed explanation of the methods. The histogram function 
in ImageJ (FIJI) was used to calculate the coefficient of variance (CV) (as SD/mean) of the histogram of different 
pixel intensities. This metric is used to quantify and discriminate between clots of naïve plasma and clots with 
added product.
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Pooled PPP to detect amyloid and SAA (with SAA antibody). SAA (30 μg.mL−1) was incubated with pooled 
healthy PPP for 30 minutes at room temperature. Amytracker 480 and 680 were added to the samples and incu-
bated at room temperature for a further 30 minutes. Clot formation was initiated with thrombin and the clots 
( ± SAA) were air-dried for 4 minutes. This was followed by fixation with 10% neutral buffered formalin (NBF). 
After phosphate-buffered saline (PBS) (pH = 7.4) washing steps, samples were blocked with 5% goat serum (in 
PBS), and incubated with anti-human SAA antibody (1:500 in goat serum) (Anti-Serum Amyloid A antibody 
[EP11592-92]; ab190802) for one hour. After further PBS washing steps, the sample was incubated with second-
ary antibody (1:500 in PBS) (Goat Anti-Mouse IgG H&L Alexa Fluor® 488; ab150113) at room temperature in 
the dark for a further hour. The samples were finally washed and a coverslip was mounted with a drop of Dako 
fluorescence mounting medium on a microscopy slide for confocal analysis. The prepared samples were viewed 
on a confocal microscope (details above). SAA-antibody was viewed at an excitation of 488 nm, with emission 
measured with a GaAsP detector at 493–630 nm. Amytracker signal was viewed as above.
Fluorescent detection of amyloid signal in purified fibrinogen and pooled platelet poor plasma 
(PPP) after addition of apolipoprotein A-I (apoA-I). Purified fibrinogen and pooled PPP were exposed 
to apoA-I (30 μg.mL−1) for 30 minutes followed by Amytracker 480 and 680 and ThT exposure for a further 
30 minutes. Clot formation was initiated by thrombin, and the sample was visualised with a confocal microscope.
Correlative light-electron microscopy (CLEM) to detect SAA (with SAA antibody detection) 
and amyloid (with Amytracker 680). CLEM is a novel procedure where a confocal micrograph is cor-
related with a scanning electron microscope (SEM) micrograph37–39. For CLEM preparation, SAA (30 μg.mL−1) 
was added to purified fibrinogen, followed by Amytracker 680 exposure and clot formation by thrombin. SAA 
was identified with anti-SAA antibody staining as described above. The prepared sample was covered with PBS 
for super-resolution (confocal) analysis, and mounted in the Zeiss Shuttle-and-Find microscope sample holder. 
This sample holder has a marked coordinate system that can be calibrated with the sample and the instrument. 
Prior to imaging the sample, the microscope is calibrated to the sample holder. For improved resolution and 
subsequent correlation, the samples were imaged with the super-resolution structured illumination microscopy 
(SR-SIM) platform. For the SAA antibody SIM detection, the 488 nm 100 mW laser was used for excitation and 
emission was detected with a BP 495–550 filter and captured with an Andor EM-CCD camera iXon DU 885. For 
Amytracker 680, the 561 nm lasers were used for excitation, with the BP 570–620 emission filter. Z-stack micro-
graphs were processed with the ZEN 2012 software, applying an optimised noise-filtering algorithm. Due to the 
multi-colour setup, a channel alignment correction was performed post-processing.
Following acquisition of the fluorescence micrographs, SEM sample preparation was immediately performed 
with the cover slip still mounted in the Shuttle and Find Holder. The sample was further fixed with 1% osmium 
tetroxide, then dehydrated using a standard series of ethanol dilutions: 30%, 50%, 70%, 90% and (3x) 100%. The 
sample was subsequently covered with 99.9% hexamethyldisilazane (HMDS) to complete sample dehydration 
and air dried in a fume hood overnight. The sample was coated with a thin (~5 nm) layer of carbon and imaged 
on a Zeiss MERLIN field emission scanning electron microscope at 1 kV using the Shuttle and Find modality to 
correlate areas of interest.
Statistical analysis. TEG parameters were analysed by either the two-tailed paired t-test or the Wilcoxon 
matched-pairs test, after normality testing. This type of analysis allows us to compare each product exposure with 
the control (GraphPad Prism 7). Coefficient of variance (CV) from the fluorescent confocal data were analysed 
using Mann-Whitney test (GraphPad Prism 7).
Data sharing. Raw data, including original images and micrographs without colour can be accessed at: 
https://1drv.ms/f/s!AgoCOmY3bkKHiOJ5yZeJLiYfzLq2yQ.
Ethics approval and consent to participate. Ethical clearance was obtained from the Health Research 
Ethics Committee (HREC) of Stellenbosch University. A written form of informed consent was obtained from 
all donors. The Universities of Pretoria and Stellenbosch (clearance numbers UP355/2015, UP298/2016 and 
UP77/2017) approved this study. Written informed consent was obtained from all donors. Blood was collected 
and methods were carried out in accordance with the relevant guidelines of the ethics committees. We adhered 
strictly to the Declaration of Helsinki.
Results
SAA promotes atypical coagulation. The coagulation properties of platelet poor plasma (PPP) and 
whole blood (WB), with or without SAA treatment, are shown in Table 2. The thromboelastography (TEG) results 
for PPP reflect the effect of the added SAA on fibrin(ogen). The data indicate that SAA added at low concentra-
tions (30 µg.ml−1) caused atypical coagulation: MA (increased clot density), MRTG (increased clot growth) and 
TTG (increased clot strength) were significantly changed. The TEG analysis of WB considers the participation 
of the formed elements in clot formation, namely platelets and RBCs, together with fibrin(ogen). TTG and MA 
were both significantly decreased, indicating a decreased clot strength with decreased platelet and/or fibrin(ogen) 
interaction, which results in a less dense clot that is also less rigid. The WB TEG results suggest a more flimsy 
clot, with few platelet interactions with (amyloidogenic) fibrin(ogen). Overall, the PPP and WB TEG results sug-
gest a fibrin(ogen)-mediated enhancement of coagulation, but an inhibition of platelet/fibrin(ogen) interaction. 
These results point towards a dichotomous, complex interaction of SAA with fibrin(ogen) as well as the formed 
elements (platelets and RBCs) in blood.
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SAA promotes platelet activation but not extensive spreading. The ultrastructure of RBC and 
platelets of healthy blood, before and after exposure to SAA is depicted in Fig. 1. Micrographs of naïve WB smears 
show the expected biconcave RBCs and slightly activated platelets with a few pseudopodia, due to contact acti-
vation (Fig. 1A–D). In Fig. 1E–I, micrographs of WB after exposure to 30 μg.mL−1 or 100 μg.mL−1 SAA, show 
RBC agglutination, platelet activation and increased platelet clumping but not platelet spreading. During a typical 
prothrombotic state, platelet activation and spreading result in an increased platelet/fibrinogen interaction. The 
platelets in this exposed WB sample show only enhanced pseudopodia formation in the presence of SAA, with-
out spreading. We include a positive control (Fig. 1J) of platelets from type 2 diabetes, where platelets show both 
activation and spreading (raw data from a recently published paper27). This observation supports the TEG results, 
where a flimsy WB clot forms with compromised platelet/(amyloidogenic) fibrin(ogen) interactions. RBC agglu-
tination will cause rheology impairment40, and provides evidence of both hypercoagulation and a pro-thrombotic 
state. Our raw dataset of micrographs can be accessed at the data sharing link given above.
SAA promotes amyloid formation in purified and FITC-fibrin(ogen). Figure 2A,B depict confocal 
microscopy results of unstained purified fibrin(ogen) clots, with and without addition of 30 μg.mL−1 SAA. The 
unstained results suggest that there are areas of auto-fluorescence in purified fibrin(ogen) clots, and these areas 
can be picked up with the laser settings of the three amyloid markers. Figure 2C shows a purified fibrin(ogen) 
clot with added Amytracker 680 (single stain). Auto-fluorescence is detected in the green channel whereas amy-
loid areas are detected with Amytracker 680 in the red channel. The auto-fluorescent and amyloid signal share a 
similar amorphous morphology and appear to overlap in certain regions. Indeed, certain amyloid proteins have 
been shown to possess auto-fluorescent properties42,43, and investigating a potential correlation been the intrinsic 
optical properties of fibrinogen and (stained) amyloid signal presents a novel research question.
Figure 2D depicts confocal microscopy results, where purified fibrinogen was incubated with 30 μg.mL−1 
SAA, together with all three fluorescent amyloid markers (Amytracker 480, 680 and ThT), and clotted with 
thrombin. Amytracker is newly developed specific amyloid stain with enhance optical properties, whereas ThT 
is a classical amyloid stain that binds to open hydrophobic areas that are considered equivalent to amyloid areas. 
ThT has a wide spectra where fluorescence can be detected35. Amytracker 480 and ThT therefore have similar 
excitation and emission spectra and we allowed these two stains, which both target amyloid structures, to overlap 
in the microscope setup to produce a combination (blue) channel of more pronounced amyloid signal, alongside 
the isolated signal from Amytracker 680’s red channel and the ThT’s isolated green channel.
Further to this, Fig. 3A,B show FITC-fibrin(ogen) clots, with and without SAA. Figure 3C shows a 
SAA-exposed FITC fibrinogen clot with added Amytracker 680. As was noted in purified fibrin(ogen) clots 
(Fig. 2C), naïve FITC-fibrin(ogen) clots also contain small areas of abnormal or misfolded protein. When SAA 
is added, larger areas of hypercoagulable fibrin(ogen) are noted in these clots. Amytracker 680 also binds in the 
same vicinity as the hypercoagulable areas. These results point to the fact that anomalous hypercoagulated areas, 
that form in the presence of SAA, have an amyloid nature. These results are in line with previous findings, where 
we showed that increased amyloid is present in fibrin(ogen) in conditions such as Type 2 Diabetes, Parkinson’s 
Disease and Alzheimer Disease, where hypercoagulation is well-known44–47.
TEG Parameters Naïve PPP +SAA P Value: Naïve vs SAA
PPP Analysis (n = 20)
R-Time 8.8 ± 1.6 8.3 ± 1.3 0.13
Angle 53.7 [51.3–56.0] 55.9 ± 6.9 0.09
MA 24.5 ± 6.2 26.0 ± 6.8 0.03
MRTG 3.5 [3.1–4.2] 4.2 [3.8–5.5] 0.002
TMRTG 10.1 ± 1.8 9.7 ± 1.6 0.17
TTG 168 ± 59 181 ± 65 0.02
TEG Parameters Naïve WB +SAA P Value: Naïve vs SAA
WB Analysis (n = 11)
R-Time 9.4 ± 2.6 8.9 ± 1.6 0.50
Angle 60.7 ± 4.8 60.6 ± 6.2 0.9
MA 61.6 ± 3.3 54.9 ± 7.0 0.01
MRTG 5.4 ± 1.0 5.2 ± 1.6 0.7
TMRTG 13.3 ± 3.5 12.7 ± 2.4 0.5
TTG 812 ± 110 628 ± 174 0.009
Table 2. TEG analysis of platelet poor plasma (PPP) and whole blood (WB) before and after exposure to SAA. 
Parametric data are reported as mean ± SD, whereas non-parametric data are given as median and interquartile 
range (25% percentile – 75% percentile). Data pairs that are parametric were assessed using the Student 
paired t-test, whereas non-parametric data pairs where assessed using the Wilcoxon signed rank test. p < 0.05 
is considered significant and are marked in bold41. R-time: reaction time (minutes); Angle: (degrees); MA: 
maximum amplitude (mm); MRTG: maximum rate of thrombus generation (Dyn.cm−2.s−1); TMRTG: time to 
maximum rate of thrombin generation (minutes); TTG: total clot strength (Dyn.cm−2).
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Finally, even though SAA is an amyloid protein itself, it does not show fluorescence when stained alone with 
amyloid markers (data not shown). We therefore suggest that the amyloid signal comes from the fibrinogen, the 
major protein in PPP, that changes in the presence of SAA to become hypercoagulated and that these hyperco-
agulated areas are indeed amyloid in nature. These results suggest that SAA, when added in a purified form, can 
induce amyloidogenesis of both purified and FITC-fibrin(ogen). We next quantitatively investigate the influence 
of SAA on healthy plasma, as well as confirm SAA interaction with fibrinogen by antibody binding and correla-
tive microscopy.
SAA induces amyloid fibrils in individual healthy plasma clots. Individual healthy PPP (n = 19) was 
incubated without or with 30 μg.mL−1 SAA, followed by exposure to the 3 amyloid fluorescent markers and clot 
preparation. Figure 4A,B represent fluorescent signals of the amyloid markers under the different exposure condi-
tions. Very little amyloid signal is seen in healthy naïve clots (Fig. 4A), while added SAA caused a marked increase 
in all 3 fluorescent marker signals (p < 0.0001), with large patches of visible amyloid (Fig. 4B). This observation 
provides evidence that the presence of free SAA circulating at the level present in a modest acute phase response 
can induce atypical clotting. Figure 5 represents the coefficient of variance (CV) data for the pixel intensities of 
the confocal microscopy data. Multiple micrographs were captured for each sample. In total, 94 control and 96 
SAA micrographs were analysed.
SAA is detected with antibody binding in the same areas as amyloid signal, in both pooled 
plasma and purified fibrinogen. To confirm that an interaction between SAA and the fibrin(ogen) pro-
tein is present, a pooled PPP smear was stained with anti-SAA fluorescent antibody, followed by addition of 
Amytracker 480 and 680 (Fig. 6). SAA could be detected with its antibody and amyloid signal was detected in 
overlapping areas to the SAA antibody.
Furthermore, correlative microscopy of a purified fibrinogen clot stained for SAA with antibody and for amy-
loid with Amytracker 680 confirms that SAA binds to purified fibrinogen, where it can provide a stimulus for 
the protein structure to become amyloidogenic. In Fig. 7A, the green antibody fluorescence is detected in close 
proximity to the red (Amytracker 680) amyloid fluorescent signal. Figure 7B represents the SEM analysis, Fig. 7C 
the SAA antibody fluorescence and Fig. 7D the Amytracker 680 fluorescence. Figure 7E shows a SEM micrograph 
Figure 1. (A–D) WB smear prepared from healthy citrated blood. (A,C) Biconcave RBCs at different 
magnifications. (B) Platelets with slight pseudopodia formation. (D) Higher magnification of a representative 
healthy platelet with slight pseudopodia formation due to contact activation. (E–I) WB smear prepared from 
healthy citrated blood after exposure to SAA. WB incubated with 30 μg.mL−1 SAA show RBC agglutination 
(E,F) and activated and aggregated platelets (G,H). (I) WB incubated with 100 μg.mL−1 SAA reveals, at higher 
magnification, agglutinated RBCs with activated platelets; arrows indicate agglutination. (J) Example of platelet 
(hyperactivation) seen in type 2 diabetes (from raw data27). See scale bar below each micrograph.
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of purified fibrinogen with added SAA, but without thrombin. These results also confirm that SAA causes soluble 
fibrinogen to polymerise into insoluble matted deposits. Incubation of purified fibrinogen with human apoA-I, 
at 30 μg.mL−1 for 30 minutes, followed by incubation with Amytracker and thrombin did not yield a fluorescent 
amyloidogenic signal (data not shown).
Discussion
Intimate associations exist between inflammation and thrombosis, with the inflammatory state promoting coagu-
lation7. These processes share key molecular mechanisms and can be viewed as intrinsically linked processes48,49. 
HDL serves as a modulator of platelet and coagulation responses50. However, inflammatory HDL is remarkably 
remodelled by acute phase SAA associating with it, to the extent that SAA can even become the major apolipopro-
tein28. This SAA, that can increase up to a thousand-fold in plasma, has been shown to impact platelet adhesion 
and activation25. However, it should be kept in mind that this SAA is not free, but mostly bound to HDL.
Here we established that free SAA, added at low physiological levels (30 µg.mL−1), representing a modest 
acute phase response, caused red blood cell agglutination, platelet activation and aggregation, but without platelet 
spreading. Platelet spreading indicates increased activation where the platelet loses its rigid structure, a process 
whereby adherent platelets will flatten at sites of vascular injury, with increased deformation of its membrane. It 
is plausible that the highly lipophilic SAA interacts within the platelet cell surface phospholipids (analogous to 
HDL) to produce these effects.
In previous work, we demonstrated that exceptionally low (and highly substoichiometric) concentrations 
of LPS, as well as LTAs, could induce the formation of an amyloid form of fibrin10. This novel finding sup-
ported previous research by Strickland and colleagues that showed that fibrin(ogen) can interact with known 
amyloid-forming peptides and proteins22,24,51–54. We established here that SAA (30 µg.mL−1) can similarly 
induce amyloid fibrin fibrils that could affect clot formation, likely in an interactive manner. We added SAA 
Figure 2. (A) Unstained purified fibrin(ogen) clots showing auto-fluorescent signal in all 3 marker channels. 
(B) Unstained purified fibrin(ogen) clots with added serum amyloid A, showing enhanced auto-fluorescent 
signal in all 3 marker channels. (C) Purified fibrin(ogen) clot with Amytracker 680. (D) Purified fibrin(ogen) 
clot with added SAA followed by Amytracker 480 (blue channel), 680 (red channel) and ThT (green channel).
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(30 µg.mL−1) to purified fibrinogen, FITC-fibrinogen and to individual and pooled donor PPP, both with and 
without thrombin. We confirmed SAA binding to purified fibrinogen and to pooled PPP with the use of fluores-
cent SAA antibody binding (Figs 6 and 7). We also showed that amyloid can be induced in purified fibrinogen, 
after exposure to SAA, and that SAA binding occurs in the same areas as the amyloid areas on fibrin(ogen), using 
CLEM technology. SAA added to purified fibrinogen also formed spontaneous dense and matted fibrin(ogen) 
deposits, without addition of thrombin (Fig. 7E). These results therefore suggest that circulating SAA might bind 
to soluble and circulating plasma molecules, such as fibrinogen, and cause structural (amyloidogenic) changes. 
These findings support our WB analysis, where we showed, that after addition of SAA, spontaneous plasma 
deposits were noted that caused RBCs to become agglutinated to each other (see Fig. 1; arrows). Incubation of 
purified fibrinogen with the apolipoprotein apoA-I (30 µg.mL−1) did not yield a fluorescent amyloid signal with 
Amytrackers.
A further interesting finding was that hypercoagulated areas (or anomalous clotted fibrin deposits) show 
auto-fluorescence in purified and FITC fibrin (ogen), as well as pooled plasma clots. Autofluorescence was previ-
ously reported in fibrin microbeads, prepared from native and heat denatured fibrinogen, activated by thrombin 
and crosslinked by endogenous factor XIII55. Furthermore, these areas bear similarities to the areas where our 
amyloid markers also bind. This is in line with previous findings that suggest that an intrinsic fluorescence, in the 
visible range, develops during the aggregation of a range of polypeptides, including the disease-related human 
peptides amyloid-β42,43.
A notable aspect of our results is that all the plasma tested contained normal levels of HDL. SAA readily asso-
ciates with HDL, but our findings indicate that sufficient “free” SAA is available to affect platelet activation and 
clot formation. It is this “free” (non HDL-associated) SAA that has been shown to be biologically active56. HDL 
Figure 3. (A) FITC fibrinogen; (B) FITC fibrinogen with added SAA; (C) FITC fibrinogen with added SAA 
and Amytracker 680 (red).
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apolipoproteins (apoA-I, SAA) exist in a dynamic equilibrium between the HDL-bound and free form57. During 
the acute phase response, HDL is drastically remodeled by the combined action of cholesterol ester transfer pro-
tein (CETP) and the acute phase induced group II secretory phospholipase A2 (sPLA2)28. The action of CETP on 
the core of the particle and sPLA2 hydrolysis of the HDL surface synergises the liberation of lipid-poor apoA-I 
and SAA. It is this free SAA that can deposit as reactive systemic amyloid fibrils during chronic inflammatory 
conditions. The lipid-poor or free SAA fraction during inflammation is thus a function of these remodeling 
Figure 4. (A) Fluorescent signals from amyloid-selective markers of thrombin-induced PPP clots from three 
representative naïve control donors. (B) Fluorescent signals from amyloid-selective markers of thrombin-
induced PPP clots from three control donors exposed to (30 μg.mL−1) SAA. (The blue channel represents signal 
from both Amytracker 480 and ThT).
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activities. As an exchangeable apolipoprotein, a non-HDL SAA concentration of 30–50 ug∙mL−1 is readily achiev-
able, even during modest inflammation58.
In addition to the huge induction of SAA during inflammation that alters HDL apolipoprotein composition, 
acute phase phospholipases are also induced59,60. They hydrolyse HDL surface phospholipids, accelerating HDL 
metabolism and impacting the ratio of HDL-associated and “free” SAA towards the latter, potentially increasing 
the pro-inflammatory and pro-coagulant form of SAA28,56. The SAA-enriched acute-phase HDL would also inter-
act with the classical HDL receptor scavenger receptor class B type I (SR-BI) resulting in selective lipid uptake 
from the particle61. SR-BI remodeling of acute-phase HDL could additionally propel SAA to a “free” form28. In 
addition, SR-BI is present on platelets where it can modulate platelet reactivity and thrombosis in dyslipidemia62.
In the present paper, we focused only on the effects of free SAA added ex vivo. However, we do appreciate that 
there are many physiological factors including the simultaneous presence of e.g. lipases, and factors such as blood 
rheology, that play important roles. Here, we confirmed that SAA added at low physiological concentrations 
(30 μg.mL−1) caused an increase in fluorescent staining in PPP, as seen by confocal microscopy, suggesting the 
formation of pathological amyloid fibrin.
The TEG, SEM and confocal amyloid marker results from both WB and PPP analyses point collectively to 
the development of a pro-coagulant state when free SAA is present. The formed clot is more fragile with possibly 
compromised platelet interactions. Overall our results suggest a fibrin(ogen)/SAA-mediated enhancement of 
coagulation, but an inhibition of platelet/fibrin(ogen) interactions; with this interaction potentially including 
amyloid fibrin(ogen). This is the result of a dichotomous complex interaction of SAA with fibrin(ogen) as well as 
the formed elements (viz. platelets and RBC) in blood. In this study, we have not investigated the mechanism by 
which SAA might exert its effects. However, mechanistically, SAA could inhibit platelet activities such as degran-
ulation, expression of GPIIb/IIIa, or contraction via microtubules. This would prevent the usual platelet-fibrin 
polymer interaction. Additionally, changes in the fibrin structure to an anomalous amyloid form may also affect 
this interaction.
Figure 5. Coefficient of variation (CV) analysis of confocal microscopy micrographs. Fluorescent results from 
samples with the three fluorescent amyloid markers: Amytracker 480 ThT combined channel, Amytracker 680 
and Thioflavin-T are presented as boxplots. Samples are naïve PPP or PPP incubated with 30 μg.mL−1 SAA. 
P-values for all three markers were < 0.0001 (****) (Mann-Whitney analysis); Coefficient of Variation (CV).
Figure 6. Pooled PPP incubated with 30 μg.mL−1 SAA followed by exposure to (A) fluorescent SAA antibody, 
(B) Amytracker 480 and (C) Amytracker 680, and clotted with thrombin.
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A clearer and more mechanistic definition of SAA impacting coagulation during inflammation is essential to 
understand better its value in diagnosis and even therapy. This would be complex in vitro given the large number 
of enzymes and receptors that affect HDL and SAA during this process. To explore these questions in vivo, animal 
Figure 7. Correlative Light Electron Microscopy (CLEM) confirms the presence of SAA in amyloidgenic 
fibrinogen clots. Purified fibrinogen was incubated with 30 μg.mL−1 SAA, and marked with Amytracker 680 
and fluorescent SAA antibody. (A–D) Fibrinogen clotted with thrombin. (A) Super-resolution micrograph 
combined with SEM micrograph using CLEM technology. (B) SEM micrograph. (C) Fluorescent SAA antibody 
micrograph. (D) Fluorescent Amytracker 680 micrograph. (E) SEM image of purified fibrinogen with SAA, but 
without thrombin (not clotted).
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models would be required where SAA genes are deleted or SAA is over-expressed with viral vectors5,63. Overall, 
the results presented in this paper demonstrate that SAA can directly bind to fibrin(ogen), and that SAA can 
affect coagulation by promoting amyloid formation in fibrin(ogen), as well as influencing platelets to be more 
prothrombotic.
References
 1. Uhlar, C. M. & Whitehead, A. S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265, 501–523 (1999).
 2. Coetzee, G. A. et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. 
J Biol Chem 261, 9644–9651 (1986).
 3. Eriksen, N. & Benditt, E. P. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density 
lipoprotein. Proc Natl Acad Sci USA 77, 6860–6864 (1980).
 4. Malle, E., Steinmetz, A. & Raynes, J. G. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 102, 
131–146 (1993).
 5. de Beer, M. C. et al. Impact of serum amyloid A on high density lipoprotein composition and levels. J Lipid Res 51, 3117–3125, 
https://doi.org/10.1194/jlr.M005413 (2010).
 6. Niemi, K. et al. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J 
Immunol 186, 6119–6128, https://doi.org/10.4049/jimmunol.1002843 (2011).
 7. Song, C. et al. Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. 
Atherosclerosis 202, 596–604, https://doi.org/10.1016/j.atherosclerosis.2008.04.049 (2009).
 8. Vitale, A. et al. Serum amyloid-A in Behcet’s disease. Clin Rheumatol 33, 1165–1167, https://doi.org/10.1007/s10067-014-2555-9 
(2014).
 9. Kell, D. B. & Pretorius, E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and 
nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol 123, 16–41, https://doi.org/10.1016/j.
pbiomolbio.2016.08.006 (2017).
 10. Pretorius, E. et al. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment 
with novel Amytracker™ stains. Royal Society Interface 15, 20170941, https://doi.org/10.1098/rsif.2017.0941 (2018).
 11. Pretorius, E., Mbotwe, S., Bester, J., Robinson, C. J. & Kell, D. B. Acute induction of anomalous and amyloidogenic blood clotting by 
molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. Journal of the Royal Society Interface 13, 
https://doi.org/10.1098/rsif.2016.0539 (2016).
 12. Stangou, A. J. et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role 
of liver transplantation. Blood 115, 2998–3007, https://doi.org/10.1182/blood-2009-06-223792 (2010).
 13. Litvinov, R. I., Faizullin, D. A., Zuev, Y. F. & Weisel, J. W. The alpha-helix to beta-sheet transition in stretched and compressed 
hydrated fibrin clots. Biophys J 103, 1020–1027, https://doi.org/10.1016/j.bpj.2012.07.046 (2012).
 14. Langkilde, A. E., Morris, K. L., Serpell, L. C., Svergun, D. I. & Vestergaard, B. The architecture of amyloid-like peptide fibrils revealed 
by X-ray scattering, diffraction and electron microscopy. Acta Crystallogr D Biol Crystallogr 71, 882–895, https://doi.org/10.1107/
s1399004715001674 (2015).
 15. Gabay, C. & Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340, 448–454, https://doi.
org/10.1056/nejm199902113400607 (1999).
 16. Husebekk, A., Skogen, B., Husby, G. & Marhaug, G. Transformation of amyloid precursor SAA to protein AA and incorporation in 
amyloid fibrils in vivo. Scand J Immunol 21, 283–287 (1985).
 17. Westermark, G. T., Fandrich, M. & Westermark, P. A. Aamyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10, 
321–344, https://doi.org/10.1146/annurev-pathol-020712-163913 (2015).
 18. Pretorius, E., du Plooy, J. N. & Bester, J. A Comprehensive Review on Eryptosis. Cell Physiology and Biochemistry 39, 1977–2000, 
https://doi.org/10.1159/000447895 (2016).
 19. Pretorius, E., Swanepoel, A. C., DeVilliers, S. & Bester, J. Blood clot parameters: Thromboelastography and scanning electron 
microscopy in research and clinical practice. Thrombosis Research 154, 59–63, https://doi.org/10.1016/j.thromres.2017.04.005 
(2017).
 20. Soma, P. & Pretorius, E. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus. 
Cardiovasc Diabetol 14, 96, https://doi.org/10.1186/s12933-015-0261-9 (2015).
 21. Soma, P., Swanepoel, A. C., du Plooy, J. N., Mqoco, T. & Pretorius, E. Flow cytometric analysis of platelets type 2 diabetes mellitus 
reveals ‘angry’ platelets. Cardiovascular Diabetology 15, 52, https://doi.org/10.1186/s12933-016-0373-x (2016).
 22. Ahn, H. J. et al. A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s 
disease mice. J Exp Med 211, 1049–1062, https://doi.org/10.1084/jem.20131751 (2014).
 23. Ahn, H. J., Chen, Z. L., Zamolodchikov, D., Norris, E. H. & Strickland, S. Interactions of beta-amyloid peptide with fibrinogen and 
coagulation factor XII may contribute to Alzheimer’s disease. Curr Opin Hematol 24, 427–431, https://doi.org/10.1097/
moh.0000000000000368 (2017).
 24. Zamolodchikov, D. et al. Biochemical and structural analysis of the interaction between beta-amyloid and fibrinogen. Blood 128, 
1144–1151, https://doi.org/10.1182/blood-2016-03-705228 (2016).
 25. Urieli-Shoval, S. et al. Adhesion of human platelets to serum amyloid A. Blood 99, 1224–1229 (2002).
 26. Zimlichman, S., Danon, A., Nathan, I., Mozes, G. & Shainkin-Kestenbaum, R. Serum amyloid A, an acute phase protein, inhibits 
platelet activation. J Lab Clin Med 116, 180–186 (1990).
 27. Pretorius, L. et al. Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol 17, 141, https://doi.org/10.1186/
s12933-018-0783-z (2018).
 28. Jahangiri, A. et al. HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 29, 261–267, https://doi.
org/10.1161/atvbaha.108.178681 (2009).
 29. Strachan, A. F. et al. Human serum amyloid A protein. The assignment of the six major isoforms to three published gene sequences 
and evidence for two genetic loci. Journal of Biological Chemistry 264, 18368–18373 (1989).
 30. Zewinger, S. et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal 36, 
3007–3016, https://doi.org/10.1093/eurheartj/ehv352 (2015).
 31. Nielsen, V. G., Kirklin, H. K., Hoogendoorn, H., Ellis, T. C. & Holman, W. L. Thromboelastographic method to quantify the 
contribution of factor XIII to coagulation kinetics. Blood coagulation & Fibrinolysis: an international journal in haemostasis and 
thrombosis 18, 145–150, https://doi.org/10.1097/MBC.0b013e32802f7d91 (2007).
 32. Nielsen, V. G., Lyerly, R. T. & Gurley, W. Q. The effect of dilution on plasma coagulation kinetics determined by thrombelastography 
is dependent on antithrombin activity and mode of activation. Anesthesia and Analgesia 99, 1587–1592, https://doi.org/10.1213/01.
ANE.0000136843.58799.AB (2004).
 33. Nielsen, V. G. & Matika, R. W. Effects of iron and carbon monoxide on Lachesis muta muta venom-mediated degradation of 
plasmatic coagulation. Hum Exp Toxicol, https://doi.org/10.1177/0960327116661401 (2016).
 34. Bester, J. & Pretorius, E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific Reports 6, 32188, 
https://doi.org/10.1038/srep32188 (2016).
13Scientific RepoRts |          (2019) 9:3102  | https://doi.org/10.1038/s41598-019-39056-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
 35. Sulatskaya, A. I., Lavysh, A. V., Maskevich, A. A., Kuznetsova, I. M. & Turoverov, K. K. Thioflavin T fluoresces as excimer in highly 
concentrated aqueous solutions and as monomer being incorporated in amyloid fibrils. Sci Rep 7, 2146, https://doi.org/10.1038/
s41598-017-02237-7 (2017).
 36. Pretorius, E., Mbotwe, S. & Kell, D. B. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma 
of poorly controlled type 2 diabetics with cardiovascular co-morbidities. Scientific Reports (Nature) In Press (2017).
 37. Goetz, J. G., Monduc, F., Schwab, Y. & Vermot, J. Using correlative light and electron microscopy to study zebrafish vascular 
morphogenesis. Methods Mol Biol 1189, 31–46, https://doi.org/10.1007/978-1-4939-1164-6_3 (2015).
 38. Onouchi, T., Shiogama, K., Mizutani, Y., Takaki, T. & Tsutsumi, Y. Visualization of Neutrophil Extracellular Traps and Fibrin 
Meshwork in Human Fibrinopurulent Inflammatory Lesions: III. Correlative Light and Electron Microscopic Study. Acta Histochem 
Cytochem 49, 141–147, https://doi.org/10.1267/ahc.16028 (2016).
 39. López, C. S. et al. A fully integrated, three-dimensional fluorescence to electron microscopy correlative workflow. Methods Cell Biol 
140, 149–164, https://doi.org/10.1016/bs.mcb.2017.03.008 (2017).
 40. Page, M. J., Bester, J. & Pretorius, E. Interleukin-12 and its procoagulant effect on erythrocytes, platelets and fibrin(nogen): the lesser 
known side of inflammation. British Journal of Hematology, https://doi.org/10.1111/bjh.15020 (2017).
 41. Broadhurst, D. & Kell, D. B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. 
Metabolomics 2, 171–196 (2006).
 42. Chan, F. T. et al. Protein amyloids develop an intrinsic fluorescence signature during aggregation. Analyst 138, 2156–2162, https://
doi.org/10.1039/c3an36798c (2013).
 43. Tikhonova, T. N. et al. Dissection of the deep-blue autofluorescence changes accompanying amyloid fibrillation. Arch Biochem 
Biophys 651, 13–20, https://doi.org/10.1016/j.abb.2018.05.019 (2018).
 44. Pretorius, E., Mbotwe, S. & Kell, D. B. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma 
of type 2 diabetics with cardiovascular co-morbidities. Sci Rep 7, 9680, https://doi.org/10.1038/s41598-017-09860-4 (2017).
 45. Pretorius, E., Page, M. J., Engelbrecht, L., Ellis, G. C. & Kell, D. B. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using 
amyloid-selective fluorescent stains. Cardiovasc Diabetol 16, 141, https://doi.org/10.1186/s12933-017-0624-5 (2017).
 46. Pretorius, E., Bester, J., Page, M. J. & Kell, D. B. The Potential of LPS-Binding Protein to Reverse Amyloid Formation in Plasma 
Fibrin of Individuals With Alzheimer-Type Dementia. Front Aging Neurosci 10, 257, https://doi.org/10.3389/fnagi.2018.00257 
(2018).
 47. Pretorius, E., Page, M. J., Mbotwe, S. & Kell, D. B. Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin 
seen or induced in Parkinson’s disease: implications. PlosOne 13, e0192121, https://doi.org/10.1371/journal.pone.0192121 (2018).
 48. Wagner, D. D. & Burger, P. C. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 23, 2131–2137, https://doi.
org/10.1161/01.Atv.0000095974.95122.Ec (2003).
 49. Nagareddy, P. & Smyth, S. S. Inflammation and thrombosis in cardiovascular disease. Current opinion in hematology 20, 457–463, 
https://doi.org/10.1097/MOH.0b013e328364219d (2013).
 50. van der Stoep, M., Korporaal, S. J. & Van Eck, M. High-density lipoprotein as a modulator of platelet and coagulation responses. 
Cardiovasc Res 103, 362–371, https://doi.org/10.1093/cvr/cvu137 (2014).
 51. Ahn, H. J. et al. Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad 
Sci 107, 21812–21817, https://doi.org/10.1073/pnas.1010373107 (2010).
 52. Cortes-Canteli, M. et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor 
to Alzheimer’s disease. Neuron 66, 695–709, https://doi.org/10.1016/j.neuron.2010.05.014 (2010).
 53. Zamolodchikov, D. & Strickland, S. Abeta delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to 
fibrin. Blood 119, 3342–3351, https://doi.org/10.1182/blood-2011-11-389668 (2012).
 54. Zamolodchikov, D. & Strickland, S. A possible new role for Abeta in vascular and inflammatory dysfunction in Alzheimer’s disease. 
Thromb Res 141(Suppl 2), S59–61, https://doi.org/10.1016/s0049-3848(16)30367-x (2016).
 55. Marx, G. et al. Heat denaturation of fibrinogen to develop a biomedical matrix. J Biomed Mater Res B Appl Biomater 84, 49–57, 
https://doi.org/10.1002/jbm.b.30842 (2008).
 56. Kim, M.-H., de Beer, M. C., Wroblewski, J. M., Webb, N. R. & de Beer, F. C. SAA does not induce cytokine production in 
physiological conditions. Cytokine 61, 506–512, https://doi.org/10.1016/j.cyto.2012.10.019 (2013).
 57. Miyazaki, O., Ogihara, J., Fukamachi, I. & Kasumi, T. Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in 
plasma. J Lipid Res 55, 214–225, https://doi.org/10.1194/jlr.M041038 (2014).
 58. Wilson, P. G. et al. Serum Amyloid A Is an Exchangeable Apolipoprotein. Arterioscler Thromb Vasc Biol 38, 1890–1900, https://doi.
org/10.1161/atvbaha.118.310979 (2018).
 59. de Beer, F. C. & Webb, N. R. Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler 
Thromb Vasc Biol 26, 1421–1422, https://doi.org/10.1161/01.ATV.0000227561.89488.9a (2006).
 60. Jin, W., Millar, J. S., Broedl, U., Glick, J. M. & Rader, D. J. Inhibition of endothelial lipase causes increased HDL cholesterol levels in 
vivo. The Journal of Clinical Investigation 111, 357–362, https://doi.org/10.1172/JCI16146 (2003).
 61. Acton, S. et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271, 518–520 (1996).
 62. Ma, Y., Ashraf, M. Z. & Podrez, E. A. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 116, 
1932–1941, https://doi.org/10.1182/blood-2010-02-268508 (2010).
 63. Wroblewski, J. M. et al. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and 
endothelial lipase. Journal of Lipid Research 52, 2255–2261, https://doi.org/10.1194/jlr.M017681 (2011).
Acknowledgements
We thank the Biotechnology and Biological Sciences Research Council (grant BB/L025752/1) as well as the 
National Research Foundation (NRF) of South Africa (91548: Competitive Program) and the Medical Research 
Council of South Africa (MRC) (Self-Initiated Research Program) for supporting this collaboration. The funders 
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 
This is paper 22 in the series “a dormant blood microbiome in chronic, inflammatory diseases.”
Author Contributions
M.P.: TEG, SEM, confocal analysis, statistics, co-writing and editing of paper; G.J.A.T.: TEG, multiplex cytokine 
analysis; J.M.N.: TEG and sample handling; A.M.E.: statistics and co-editing of paper; T.A.N.: statistics; W.J.S.d.V.: 
editing of paper; M.c.d.B.: SAA, ApoA1 preparation and editing of paper; L.E.: CLEM; D.B.K.: editing of paper; 
E.P.: study leader and corresponding author, confocal analysis, SEM analysis CLEM, statistical analysis, writing 
of paper.
Additional Information
Competing Interests: The authors (E.P., D.B.K. and W.J.S.d.V.) have a registered patent that detects both 
amyloid and the concentration of SAA in a blood.
1 4Scientific RepoRts |          (2019) 9:3102  | https://doi.org/10.1038/s41598-019-39056-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
